Literature DB >> 6213196

In vitro susceptibility of cephalothin-resistant Enterobacteriaceae and Pseudomonas aeruginosa to Amikacin and selected new beta-lactam agents.

B T McNamara, R D Meyer, K A Pasiecznik.   

Abstract

Amikacin was evaluated in vitro by agar dilution testing against 148 different clinical isolates of cephalothin-resistant Enterobacteriaceae and Pseudomonas aeruginosa in parallel with cephalothin, cefoxitin, moxalactam, N-formimidoyl thienamycin, ceftriaxone, and cefmenoxime. Cefsulodin was also evaluated against 39 isolates of P. aeruginosa. More than 80% of all isolates tested were also gentamicin resistant, as determined by disk testing. Moxalactam and amikacin had comparable high activities against Proteus species, Escherichia coli, Serratia species, and Providencia species, and both amikacin and N-formimidoyl thienamycin had comparably high activities against the Klebsiella-Enterobacter group. N-Formimidoyl thienamycin was the most active agent against P. aeruginosa, followed by cefsulodin and amikacin.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6213196      PMCID: PMC182006          DOI: 10.1128/AAC.21.5.753

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  Antibacterial activity of selected beta-lactam and aminoglycoside antibiotics against cephalothin-resistant Enterobacteriaceae.

Authors:  R P Lewis; R D Meyer; L L Kraus
Journal:  Antimicrob Agents Chemother       Date:  1976-05       Impact factor: 5.191

2.  Thienamycin: new beta-lactam antibiotic with potent broad-spectrum activity.

Authors:  S S Weaver; G P Bodey; B M LeBlanc
Journal:  Antimicrob Agents Chemother       Date:  1979-04       Impact factor: 5.191

Review 3.  Changing patterns of susceptibility of common bacterial pathogens to antimicrobial agents.

Authors:  M Finland
Journal:  Ann Intern Med       Date:  1972-06       Impact factor: 25.391

4.  Antibiotic susceptibility testing by a standardized single disk method.

Authors:  A W Bauer; W M Kirby; J C Sherris; M Turck
Journal:  Am J Clin Pathol       Date:  1966-04       Impact factor: 2.493

5.  Amikacin therapy for serious gram-negative bacillary infections.

Authors:  R D Meyer; R P Lewis; E D Carmalt; S M Finegold
Journal:  Ann Intern Med       Date:  1975-12       Impact factor: 25.391

6.  Emergence of gentamicin- and carbenicillin-resistant Pseudomonas aeruginosa in a hospital environment.

Authors:  W Gaman; C Cates; C F Snelling; B Lank; A R Ronald
Journal:  Antimicrob Agents Chemother       Date:  1976-03       Impact factor: 5.191

7.  Gentamicin-resistant Pseudomonas aeruginosa and Serratia marcescens in a general hospital.

Authors:  R D Meyer; R P Lewis; J Halter; M White
Journal:  Lancet       Date:  1976-03-13       Impact factor: 79.321

8.  Thienamycin, a new beta-lactam antibiotic. I. Discovery, taxonomy, isolation and physical properties.

Authors:  J S Kahan; F M Kahan; R Goegelman; S A Currie; M Jackson; E O Stapley; T W Miller; A K Miller; D Hendlin; S Mochales; S Hernandez; H B Woodruff; J Birnbaum
Journal:  J Antibiot (Tokyo)       Date:  1979-01       Impact factor: 2.649

9.  SCE-129, antipseudomonal cephalosporin: in vitro and in vivo antibacterial activities.

Authors:  K Tsuchiya; M Kondo; H Nagatomo
Journal:  Antimicrob Agents Chemother       Date:  1978-02       Impact factor: 5.191

10.  Activity of five aminoglycoside antibiotics in vitro against gram-negative bacilli and Staphylococcus aureus.

Authors:  L S Young; W L Hewitt
Journal:  Antimicrob Agents Chemother       Date:  1973-12       Impact factor: 5.191

View more
  4 in total

Review 1.  Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  D M Richards; R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-06       Impact factor: 9.546

Review 2.  Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  S P Clissold; P A Todd; D M Campoli-Richards
Journal:  Drugs       Date:  1987-03       Impact factor: 9.546

Review 3.  Cefmenoxime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; P A Todd
Journal:  Drugs       Date:  1987-08       Impact factor: 9.546

4.  Efficacy and safety of ceftriaxone in serious pediatric infections.

Authors:  S C Aronoff; D Murdell; C A O'Brien; J D Klinger; M D Reed; J L Blumer
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.